In this Timeline, we describe the characteristics of tumour antigens that are recognized by spontaneous T cell responses in cancer patients and the paths that led to their identification. We explain on what genetic basis most, but not all, of these antigens are tumour specific: that is, present on tumour cells but not on normal cells. We also discuss how strategies that target these tumour-specific antigens can lead either to tumour-specific or to crossreactive T cell responses, which is an issue that has important safety implications in immunotherapy. These safety issues are even more of a concern for strategies targeting antigens that are not known to induce spontaneous T cell responses in patients.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Klein, G. & Klein, E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc. Natl Acad. Sci. USA 74, 2121–2125 (1977).
Gross, L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 326–333 (1943).
Prehn, R. T. & Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769–778 (1957).
Hewitt, H. B., Blake, E. R. & Walder, A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33, 241–259 (1976).
Boon, T. & Kellermann, O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl Acad. Sci. USA 74, 272–275 (1977).
Boon, T., Kellermann, O., Mathy, E. & Gaillard, J. A. in Teratomas and Differentiation (eds Sherman, M. & Solter, D.) 161–166 (Academic Press, 1975).
Boon, T. & Van Pel, A. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl Acad. Sci. USA 75, 1519–1523 (1978).
Van Pel, A. & Boon, T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl Acad. Sci. USA 79, 4718–4722 (1982).
Claman, H. N., Chaperon, E. A. & Triplett, R. F. Thymus-marrow cell combinations. synergism in antibody production. Proc. Soc. Exp. Biol. Med. 122, 1167–1171 (1966).
Miller, J. F. A. P. & Mitchell, G. F. The thymus and the precursors of antigen reactive cells. Nature 216, 659–663 (1967).
Cerottini, J. C. & Brunner, K. T. Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv. Immunol. 18, 67–132 (1974).
Rouse, B. T., Rollinghoff, M. & Warner, N. L. Anti-theta serum-induced supression of the cellular transfer of tumour-specific immunity to a syngeneic plasma cell tumour. Nature New Biol. 238, 116–117 (1972).
Uyttenhove, C., Van Snick, J. & Boon, T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J. Exp. Med. 152, 1175–1183 (1980).
Boon, T., Van Snick, J., Van Pel, A., Uyttenhove, C. & Marchand, M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J. Exp. Med. 152, 1184–1193 (1980).
Gillis, S. & Smith, K. A. Long term culture of tumour-specific cytotoxic T cells. Nature 268, 154–156 (1977).
Maryanski, J. L., Van Snick, J., Cerottini, J. C. & Boon, T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur. J. Immunol. 12, 401–406 (1982).
Maryanski, J. L., Marchand, M., Uyttenhove, C. & Boon, T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Int. J. Cancer 31, 119–123 (1983).
Uyttenhove, C., Maryanski, J. & Boon, T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040–1052 (1983).
Wheelock, E. F., Weinhold, K. J. & Levich, J. The tumor dormant state. Adv. Cancer Res. 34, 107–140 (1981).
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002).
Zinkernagel, R. M. & Doherty, P. C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701–702 (1974).
Townsend, A. R. M. et al. The epitopes of Influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959–968 (1986).
Bjorkman, P. et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506 (1987).
Van Pel, A., De Plaen, E. & Boon, T. Selection of highly transfectable variant from mouse mastocytoma P815. Somat Cell. Mol. Genet. 11, 467–475 (1985).
De Plaen, E. et al. Immunogenic (tum−) variants of mouse tumor P815: cloning of the gene of tum− antigen P91A and identification of the tum− mutation. Proc. Natl Acad. Sci. USA 85, 2274–2278 (1988).
Lurquin, C. et al. Structure of the gene of tum− transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58, 293–303 (1989).
Szikora, J. P. et al. Structure of the gene of tum− transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J. 9, 1041–1050 (1990).
Sibille, C. et al. Structure of the gene of tum− transplantation antigen P198: a point mutation generates a new antigenic peptide. J. Exp. Med. 172, 35–45 (1990).
Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E. & Boon, T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373–1384 (1991).
Ramarathinam, L. et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 155, 5323–5329 (1995).
Boon, T. et al. Genes coding for tumor-specific rejection antigens. Cold Spring Harb. Symp. Quant. Biol. 59, 617–622 (1994).
Brandle, D. et al. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28, 4010–4019 (1998).
Livingston, P. O. et al. Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int. J. Cancer 24, 34–44 (1979).
Vanky, F. & Klein, E. Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int. J. Cancer 29, 547–553 (1982).
Vose, B. M. & Bonnard, G. D. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2. Int. J. Cancer 29, 33–39 (1982).
Knuth, A., Danowski, B., Oettgen, H. F. & Old, L. J. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl Acad. Sci. USA 81, 3511–3515 (1984).
Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988).
Hérin, M. et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer 39, 390–396 (1987).
Van den Eynde, B. et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer 44, 634–640 (1989).
van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991).
Fiszer, D. & Kurpisz, M. Major histocompatibility complex expression on human, male germ cells: a review. Am. J. Reprod. Immunol. 40, 172–176 (1998).
Traversari, C. et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176, 1453–1457 (1992).
De Plaen, E. et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40, 360–369 (1994).
Lurquin, C. et al. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics 46, 397–408 (1997).
Muscatelli, F., Walker, A. P., De Plaen, E., Stafford, A. N. & Monaco, A. P. Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc. Natl Acad. Sci. USA 92, 4987–4991 (1995).
Lucas, S., De Plaen, E. & Boon, T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 87, 55–60 (2000).
Lucas, S. et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. 58, 743–752 (1998).
Boël, P. et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2, 167–175 (1995).
Van den Eynde, B. et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182, 689–698 (1995).
Coulie, P. G. et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92, 7976–7980 (1995).
Wölfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).
Brandle, D., Brasseur, F., Weynants, P., Boon, T. & Van den Eynde, B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183, 2501–2508 (1996).
Robbins, P. F. et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185–1192 (1996).
Brichard, V. et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489–495 (1993).
Topalian, S. L. et al. Melanoma-specific CD4+T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183, 1965–1971 (1996).
Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA 92, 11810–11813 (1995).
Smith, H. A. & McNeel, D. G. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin. Dev. Immunol. 2010, 150591 (2010).
Chen, Y. T. et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94, 1914–1918 (1997).
Chen, Y.-T. Identification of human tumor antigens by serological expression cloning: an online review on SEREX. Cancer Immun. [online], (2004).
Rotzschke, O. et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348, 252–254 (1990).
Cox, A. L. et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716–719 (1994).
Skipper, J. C. et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183, 527–534 (1996).
Dalet, A. et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl Acad. Sci. USA 108, E323–E331 (2011).
Parker, K. C., Bednarek, M. A. & Coligan, J. E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163–175 (1994).
Rammensee, H.-G., Bachmann, J. & Stevanović, S. MHC Ligands and Peptide Motifs (Springer, 1997).
van der Bruggen, P. et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24, 3038–3043 (1994).
Chaux, P. et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163, 2928–2936 (1999).
Chaux, P. et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J. Exp. Med. 189, 767–778 (1999).
van der Bruggen, P. et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188, 51–64 (2002).
Gambacorti-Passerini, C. et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR α present in acute promyelocytic leukemia cells. Blood 81, 1369–1375 (1993).
ten Bosch, G. J., Joosten, A. M., Kessler, J. H., Melief, C. J. & Leeksma, O. C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88, 3522–3527 (1996).
Tsang, K. Y. et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87, 982–990 (1995).
van der Bruggen, P., Stroobant, V., Vigneron, N. & Van den Eynde, B. Peptide database: T cell-defined tumor antigens. Cancer Immun. [online], (2013).
Long, H. M., Parsonage, G., Fox, C. P. & Lee, S. P. Immunotherapy for Epstein-Barr virus-associated malignancies. Drug News Perspect. 23, 221–228 (2010).
van der Burg, S. H. & Melief, C. J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 23, 252–257 (2011).
Fujita, Y., Rooney, C. M. & Heslop, H. E. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 41, 193–198 (2008).
Ramos, J. C. & Lossos, I. S. Newly emerging therapies targeting viral-related lymphomas. Curr. Oncol. Rep. 13, 416–426 (2011).
Lennerz, V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013–16018 (2005).
Network, C. G. A. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Mandruzzato, S., Brasseur, F., Andry, G., Boon, T. & van der Bruggen, P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186, 785–793 (1997).
Yotnda, P. et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101, 2290–2296 (1998).
Yotnda, P. et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102, 455–462 (1998).
Makita, M. et al. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia 16, 2400–2407 (2002).
Yun, C. et al. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 54, 153–161 (1999).
Boczkowski, D., Nair, S. K., Nam, J. H., Lyerly, H. K. & Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028–1034 (2000).
Van Tendeloo, V. F. et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98, 49–56 (2001).
Weber, J. et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54, 1766–1771 (1994).
De Smet, C. et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93, 7149–7153 (1996).
Grunau, C. et al. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 43, 11–24 (2005).
Gjerstorff, M. F., Kock, K., Nielsen, O. & Ditzel, H. J. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Hum. Reprod. 22, 953–960 (2007).
Wölfel, T. et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24, 759–764 (1994).
Coulie, P. G. et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35–42 (1994).
Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347–352 (1994).
Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91, 3515–3519 (1994).
Bakker, A. B. et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62, 97–102 (1995).
Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91, 6458–6462 (1994).
Pittet, M. J. et al. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190, 705–715 (1999).
Lonchay, C. et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14631–14638 (2004).
Chaux, P., Vantomme, V., Coulie, P., Boon, T. & van der Bruggen, P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer 77, 538–542 (1998).
Alanio, C., Lemaitre, F., Law, H. K., Hasan, M. & Albert, M. L. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 115, 3718–3725 (2010).
Zippelius, A. et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195, 485–494 (2002).
Romero, P. et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188, 1641–1650 (1998).
Correale, P. et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl Cancer Inst. 89, 293–300 (1997).
Olson, B. M. et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol. Immunother. 59, 943–953 (2010).
Fisk, B., Blevins, T. L., Wharton, J. T. & Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181, 2109–2117 (1995).
Inoue, K. et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405–1412 (1997).
Cilloni, D. et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16, 2115–2121 (2002).
Chapuis, A. G. et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 5, 174ra27 (2013).
Vlad, A. M., Kettel, J. C., Alajez, N. M., Carlos, C. A. & Finn, O. J. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249–293 (2004).
Giraud, M. et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 448, 934–937 (2007).
Gotter, J., Brors, B., Hergenhahn, M. & Kyewski, B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199, 155–166 (2004).
Huijbers, I. J. et al. Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. J. Immunol. 188, 111–121 (2012).
Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691–2697 (2012).
Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151 (2013).
Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 122, 863–871 (2013).
Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011).
Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).
Quaglino, P. et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann. Oncol. 21, 409–414 (2010).
Khammari, A. et al. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol. Immunother. 56, 1853–1860 (2007).
Yeh, S. et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116, 981–989 (2009).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 305, 200–205 (2004).
Gattinoni, L., Powell, D. J. Jr, Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nature Rev. Immunol. 6, 383–393 (2006).
Germeau, C. et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201, 241–248 (2005).
Lurquin, C. et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201, 249–257 (2005).
Carrasco, J. et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 180, 3585–3593 (2008).
Coulie, P. G. et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50, 289–297 (1992).
Boon, T., Coulie, P. G., Van den Eynde, B. J. & van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175–208 (2006).
Gajewski, T. F. et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131–145 (2006).
Guillaume, B. et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc. Natl Acad. Sci. USA 107, 18599–18604 (2010).
Morel, S. et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12, 107–117 (2000).
Schultz, E. S. et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 195, 391–399 (2002).
Chapiro, J. et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176, 1053–1061 (2006).
Guillaume, B. et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J. Immunol. 189, 3538–3547 (2012).
Hanada, K., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252–256 (2004).
Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587–590 (2004).
Parmentier, N. et al. Production of an antigenic peptide by insulin-degrading enzyme. Nature Immunol. 11, 449–454 (2010).
Kessler, J. H. et al. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nature Immunol. 12, 45–53 (2011).
Rogner, U. C., Wilke, K., Steck, E., Korn, B. & Poustka, A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 29, 725–731 (1995).
Doyle, J. M., Gao, J., Wang, J., Yang, M. & Potts, P. R. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 39, 963–974 (2010).
Monte, M. et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA 103, 11160–11165 (2006).
Yang, B. et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67, 9954–9962 (2007).
Bai, S., He, B. & Wilson, E. M. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol. Cell. Biol. 25, 1238–1257 (2005).
Wang, J. et al. Induced malignant genome reprogramming in somatic cells by testis-specific factors. Biochim. Biophys. Acta 1809, 221–225 (2011).
Laduron, S. et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res. 32, 4340–4350 (2004).
Nagao, T. et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J. Biol. Chem. 278, 10668–10774 (2003).
Peikert, T., Specks, U., Farver, C., Erzurum, S. C. & Comhair, S. A. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res. 66, 4693–4700 (2006).
Gaugler, B. et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921–930 (1994).
Duffour, M.-T. et al. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur. J. Immunol. 29, 3329–3337 (1999).
Panelli, M. C. et al. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol. 164, 4382–4392 (2000).
Ma, W. et al. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int. J. Cancer 109, 698–702 (2004).
Ruault, M. et al. New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur. J. Hum. Genet. 10, 833–840 (2002).
Ruault, M. et al. BAGE genes generated by juxtacentromeric reshuffling in the Hominidae lineage are under selective pressure. Genomics 81, 391–399 (2003).
Gjerstorff, M. F. & Ditzel, H. J. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens 71, 187–192 (2008).
Cilensek, Z. M., Yehiely, F., Kular, R. K. & Deiss, L. P. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-γ, taxol and γ-irradiation. Cancer Biol. Ther. 1, 380–387 (2002).
Zendman, A. J., Van Kraats, A. A., Weidle, U. H., Ruiter, D. J. & Van Muijen, G. N. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. Int. J. Cancer 99, 361–369 (2002).
Shimono, M. et al. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells. Int. J. Oncol. 30, 835–840 (2007).
Jager, E. et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265–270 (1998).
Chen, Y. T. et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl Acad. Sci. USA 95, 6919–6923 (1998).
Güre, A. O., Wei, I. J., Old, L. J. & Chen, Y. T. The SSX gene family: characterization of 9 complete genes. Int. J. Cancer 101, 448–453 (2002).
Lim, F. L., Soulez, M., Koczan, D., Thiesen, H. J. & Knight, J. C. A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 17, 2013–2018 (1998).
Thaete, C. et al. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum. Mol. Genet. 8, 585–591 (1999).
Ayyoub, M. et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168, 1717–1722 (2002).
Yang, R., Morosetti, R. & Koeffler, H. P. Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res. 57, 913–920 (1997).
Wolgemuth, D. J. Function of the A-type cyclins during gametogenesis and early embryogenesis. Results Probl. Cell Differ. 53, 391–413 (2011).
Ochsenreither, S. et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 119, 5492–5501 (2012).
Fukuyama, T. et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 66, 4922–4928 (2006).
Park, H. J. et al. The centrosomal localization of KM-HN-1 (MGC33607) depends on the leucine zipper motif and the C-terminal coiled-coil domain. Exp. Mol. Med. 39, 828–838 (2007).
Monji, M. et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin. Cancer Res. 10, 6047–6057 (2004).
Martelange, V., De Smet, C., De Plaen, E., Lurquin, C. & Boon, T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res. 60, 3848–3855 (2000).
Miyahara, Y. et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin. Cancer Res. 11, 5581–5589 (2005).
Lim, S. H., Wang, Z., Chiriva-Internati, M. & Xue, Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 97, 1508–1510 (2001).
Frayne, J. & Hall, L. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction 124, 767–774 (2002).
Chiriva-Internati, M., Wang, Z., Pochopien, S., Salati, E. & Lim, S. H. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int. J. Cancer 107, 863–865 (2003).
Lucas, S., Brasseur, F. & Boon, T. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res. 59, 4100–4103 (1999).
Chomez, P. et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61, 5544–5551 (2001).
Alpen, B., Gure, A. O., Scanlan, M. J., Old, L. J. & Chen, Y. T. A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. Gene 297, 141–149 (2002).
Egland, K. A., Kumar, V., Duray, P. & Pastan, I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol. Cancer Ther. 1, 441–450 (2002).
Türeci, Ö. et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56, 4766–4772 (1996).
Smith, H. A., Cronk, R. J., Lang, J. M. & McNeel, D. G. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res. 71, 6785–6795 (2011).
Brunner, K. T., Mauel, J., Cerottini, J.-C. & Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14, 181–196 (1968).
Holm, G. & Perlmann, P. Quantitative studies on phytohaemagglutinin-induced cytotoxicity by human lymphocytes against homologous cells in tissue culture. Immunology 12, 525–536 (1967).
Levy, J. P. & Leclerc, J. C. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology? Adv. Cancer Res. 24, 1–66 (1977).
Bjorkman, P. J. et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329, 512–518 (1987).
Topalian, S. L. et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl Acad. Sci. USA 91, 9461–9465 (1994).
Lethé, B. et al. LAGE-1, a new gene with tumor specificity. Int. J. Cancer 76, 903–908 (1998).
Guilloux, Y. et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183, 1173–1183 (1996).
Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F. & Rosenberg, S. A. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183, 1131–1140 (1996).
Lupetti, R. et al. Translation of a retained intron in tyrosinase-related protein (TRP)-2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J. Exp. Med. 188, 1005–1016 (1998).
Van den Eynde, B. J. et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J. Exp. Med. 190, 1793–1800 (1999).
Aarnoudse, C. A., van den Doel, P. B., Heemskerk, B. & Schrier, P. I. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 82, 442–448 (1999).
Probst-Kepper, M. et al. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J. Exp. Med. 193, 1189–1198 (2001).
Ohminami, H., Yasukawa, M. & Fujita, S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95, 286–293 (2000).
The authors thank S. Depelchin and J. Klein for editorial work, and D. Godelaine and A. Van Pel for reviewing the manuscript.
Patents on human tumour antigens owned by the Ludwig Institute. Part of licence fees. P.G.C., T.B., B.J.V and P.V.
- Adoptive transfer
In cancer immunotherapy, the infusion into patients of autologous antitumour T cells that have been amplified in vitro. The lymphocytes can also be transduced with retroviral expression vectors in order to express a given T cell receptor or other gene products.
Hyporesponsiveness or unresponsiveness of T lymphocytes after recognition of their antigen.
- Central tolerance
The deletion or inactivation of immature autoreactive B cells and T cells of the primary lymphoid organs: the bone marrow (B cells) and the thymus (T cells). The remaining mature autoreactive B cells and T cells are dealt with by the mechanisms of peripheral tolerance.
The removal of an amide group. In N-glycosylated proteins, deglycosylation of an asparagine by the peptide N-glycanase generates an aspartate by deamidation. This can result in an antigenic peptide.
The molecular configuration of a peptide that is recognized by a T cell receptor or by an antibody.
The elimination of lymphocytes by a combination of lymphocyte-depleting chemotherapy (cyclophosphamide and fludarabine) and total body irradiation.
- Serological analysis of recombinant cDNA expression libraries
(SEREX). A procedure whereby proteins from human tumours are screened for recognition by autologous serum.
- Thymic epithelial cells
The thymus contains developing T lymphocytes and a stroma that consists of epithelial cells and dendritic cells. Epithelial cells of the thymic medulla, in which the transcription factor autoimmune regulator controls the expression of peripheral tissue antigens, contribute to the induction of central tolerance for T lymphocytes.
Inflammation of the uvea, which is the middle layer of the eye, between the retina and the sclera.
About this article
Cite this article
Coulie, P., Van den Eynde, B., van der Bruggen, P. et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14, 135–146 (2014). https://doi.org/10.1038/nrc3670
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies
Oral Oncology (2021)
Current Opinion in Genetics & Development (2021)
Communications Biology (2021)